Benjamin Hohl - Jun 27, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Benjamin Hohl
Stock symbol
ELVN
Transactions as of
Jun 27, 2024
Transactions value $
-$85,382
Form type
4
Date filed
7/1/2024, 08:03 PM
Previous filing
May 30, 2024
Next filing
Jul 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $10.5K +4.25K $2.48 4.25K Jun 27, 2024 Direct F1
transaction ELVN Common Stock Sale -$27.9K -1.28K -30.12% $21.79 2.97K Jun 27, 2024 Direct F1, F2
transaction ELVN Common Stock Sale -$41.3K -1.83K -61.62% $22.58 1.14K Jun 27, 2024 Direct F1, F3
transaction ELVN Common Stock Sale -$26.7K -1.14K -100% $23.43 0 Jun 27, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -4.25K -1.96% $0.00 213K Jun 27, 2024 Common Stock 4.25K $2.48 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $21.145 to $22.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $22.2058 to $23.1325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $23.37 to $23.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.